Cain B S, Meldrum D R, Meng X, Shames B D, Banerjee A, Harken A H
Department of Surgery, University of Colorado Health Sciences Center, Denver 80262, USA.
Ann Thorac Surg. 1998 Apr;65(4):1065-70. doi: 10.1016/s0003-4975(98)00093-9.
Ischemic stress and other protein kinase C (PKC)-linked receptor stimuli can induce rapid cardiac protection against ischemia-reperfusion injury. We and others have demonstrated that exogenous calcium (Ca2+) pretreatment confers PKC-mediated cardiac functional and infarct protection in animal models, but it remains unknown whether Ca2+ preconditioning confers similar postischemic functional protection in human myocardium, and, if so, whether the mechanism is mediated by PKC. We postulated that Ca2+ preconditioning confers ischemic tolerance to human myocardium by a PKC-dependent mechanism.
Human atrial trabeculae were suspended in organ baths and paced at 1 Hz, and force development was recorded. After 90 minutes of equilibration, all trabeculae were subjected to ischemia (45 minutes) and reperfusion (120 minutes). Exogenous CaCl2 (3.0 mmol/L for 5 minutes) or vehicle (saline solution) was administered before simulated ischemia, with or without concurrent PKC inhibition (bisindolylmaleimide I, 150 nmol/L).
Ischemia-reperfusion resulted in decreased postischemic developed force, Ca2+ preconditioning protected human myocardium against ischemia-reperfusion injury (p < 0.05 versus control ischemia-reperfusion), and concurrent PKC inhibition abolished the salutary effect of Ca2+ preconditioning in human myocardium (p < 0.05 versus Ca2+ preconditioning).
Preconditioning with Ca2+ represents a potent means of accessing PKC-mediated protection of the human myocardium against ischemia-reperfusion injury.
缺血应激及其他与蛋白激酶C(PKC)相关的受体刺激可诱导心脏快速产生抗缺血-再灌注损伤的保护作用。我们及其他研究者已证实,外源性钙(Ca2+)预处理可在动物模型中赋予PKC介导的心脏功能及梗死保护作用,但Ca2+预处理是否能在人类心肌中产生类似的缺血后功能保护作用,以及如果能,其机制是否由PKC介导,目前尚不清楚。我们推测Ca2+预处理通过PKC依赖机制赋予人类心肌缺血耐受性。
将人房小梁悬挂于器官浴槽中,以1Hz频率起搏,并记录其张力发展情况。平衡90分钟后,所有小梁均经历缺血(45分钟)和再灌注(120分钟)。在模拟缺血前给予外源性氯化钙(3.0mmol/L,持续5分钟)或溶剂(盐溶液),同时或不同时给予PKC抑制(双吲哚马来酰亚胺I,150nmol/L)。
缺血-再灌注导致缺血后张力发展降低,Ca2+预处理可保护人类心肌免受缺血-再灌注损伤(与对照缺血-再灌注相比p<0.05),同时PKC抑制消除了Ca2+预处理对人类心肌的有益作用(与Ca2+预处理相比p<0.05)。
Ca2+预处理是实现PKC介导的保护人类心肌免受缺血-再灌注损伤的有效手段。